{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of the TRIFLO Heart Valve"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was computer-generated"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults undergoing aortic valve replacement, eligible if they had severe aortic stenosis."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received the TRIFLO Heart Valve, while the control group received the On-X valve."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates a novel tri-leaflet mechanical valve designed to reduce thrombogenicity without long-term anticoagulation."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of major bleeding events at 12 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 8 participants were randomised: 6 to the TRIFLO group and 2 to the control group."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All participants were analysed per protocol."
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "The TRIFLO group showed no major bleeding events, while the control group had none."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials.gov NCT05687448"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study received funding from Novostia, Switzerland."
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}